View Author
patient jtk -652 narlaprevir study treatment genotype -652 virus hepatitis sample infection hepg 2 cells period ritonavir hepatitis c patients 2.0 inhibitor assay hcv-rna plasma peg-ifn-a -2b concentration protease result pharmacokinetic pseudotype dosing level placebo therapy cohort hcv genotype 1 roche effect realtime hepatitis c virus peg-ifn-a hepatitis c activity safety phase combination table performance value hcv rna entry hcv-rna levels inhibition hcv pseudotype virus decline ribavirin detection platform 7 cells center treatment-experienced patients signi ficantly signi response protein 1.0 regimen fication netherland treatment-na hepatology analysis bdna assay figure cd 81 randomized quanti fication 100 mg volunteer envelope baseline target replicon hcvpv
3 Most Recent Publications
|
Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA
(Article)
Pas, S.D. Molenkamp, R. Schinkel, J. Rebers, S. Copra, C. Seven-Deniz, S. Thamke, D. Knegt, R.J. de Haagmans, B.L. Schutten, M. |
2013-01-01
|
|
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
(Article)
Bruijne, J. Bergmann, J.F. Lier, J.J. Vliet, A.A. Janssen, H.L.A. Knegt, R.J. de Reesink, H.W. Weegink, C.J. Molenkamp, R. Schinkel, J. Tong, X. Li, J. Treitel, M.A. Hughes, E.A. |
2010-11-01
|
|
Safety and antiviral activity of JTK-652: A novel HCV infection inhibitor
(Article)
Bruijne, J. Bergmann, J.F. Schinkel, J. Reesink, H.W. Janssen, H.L.A. Weegink, C.J. Nieuwkerk, C.M.J. van Knegt, R.J. de Komoda, Y. Rooij, J.J.V.D.W. de Vliet, A.A. Jansen, P.L.M. Molenkamp, R. |
2010-10-08
|
